Ingenuity Systems Announces Multi-Year Agreement with Boehringer Ingelheim
News Jun 04, 2008
Ingenuity Systems announced the signing of a four year agreement with Boehringer Ingelheim for Ingenuity Pathway Analysis (IPA). IPA will be used throughout the Boehringer Ingelheim research and development organization to unlock novel insights from experimental data and as a general tool for biological search and exploration.
The agreement provides global access for Boehringer Ingelheim research scientists to access to the recently released IPA 6, which includes new biological and chemical content, in addition to Path Designer, an award-winning set of tools that more clearly communicates information about networks and pathways.
"We are pleased at this opportunity to become a strategic partner in Boehringer Ingelheim's research and development efforts," stated Jake Leschly, CEO, Ingenuity Systems.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.